IMCR
Immunocore Holdings Ltd
29.70$
-2.7%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +4.6% | +25.9% | +6.9% | +6.4% | +4.7% | +11.7% | +4.3% | +5.8% | -25.3% | +37.8% | +8.7% | – | |
| – | -90.3% | +54.1% | +593.9% | -73.8% | -26.3% | +151.8% | +25.2% | -50.7% | +411.0% | -83.4% | +150.7% | – | |
| – | +7.6% | +25.8% | +4.9% | +8.3% | +4.9% | +11.1% | +4.2% | +6.5% | -27.5% | +42.0% | +8.1% | – | |
| – | +10.4% | +58.0% | -11.1% | +3.3% | +15.3% | -7.2% | +22.2% | +2.3% | -17.2% | +4.6% | +21.0% | – | |
| – | +101.1% | -16.4% | -34.9% | -6.6% | +107.0% | -18.8% | +6.5% | -7.0% | +7.2% | -11.2% | +16.0% | – | |
| – | +11.5% | +39.3% | -7.3% | -1.6% | +16.8% | -6.3% | +15.7% | -1.3% | -19.0% | +10.7% | +19.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | -141.2% | – | |
| – | -4.6% | +212.7% | +16.2% | +0.4% | +84.5% | -56.6% | +1.9% | -1.2% | +0.3% | -24.3% | +32.6% | – | |
| – | -1,218.0% | – | – | – | -507.4% | – | -259.3% | – | -3,950.2% | – | -103.9% | – | |
| – | – | – | +316.2% | -277.9% | – | – | -42.9% | -179.4% | – | -97.2% | -2.2% | – | |
| – | -895.2% | – | – | – | -372.1% | – | -305.1% | – | -2,937.8% | – | -106.2% | – | |
| – | -547.6% | – | – | – | -240.0% | – | -164.2% | – | -293.8% | – | -78.4% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.